institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published 6 days ago • loading... • Updated 6 days ago

Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema (DME)

Summary by Arizona Daily Sun

EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6RImprovements in Visual Acuity and Retinal Edema Observed at All Dose LevelsNo Safety Issues Observed Following a Single Intravitreal (IVT) InjectionMultiple Ascending Dose Study Planned for Q3 2025 in DME

10 Articles

10 Articles

All

Left

1

Center

5

Right

Hanford Sentinel

+9 Reposted by 9 other sources

Eluminex Biosciences Announces Phase 1b Single Ascending Dose Study Results of a Novel Pentavalent Trispecific Fusion Antibody (EB-105) in Patients with Diabetic Macular Edema (DME)

EB-105 Targets VEGF-A, -B, PlGF, Ang-2, and IL-6RImprovements in Visual Acuity and Retinal Edema Observed at All Dose LevelsNo Safety Issues Observed Following a Single Intravitreal (IVT) InjectionMultiple Ascending Dose Study Planned for Q3 2025 in DME

6 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources10

Leaning Left1Leaning Right0Center5Last Updated5 days agoBias Distribution

83% Center

Bias Distribution

83% of the sources are Center

83% Center

Untracked bias

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States 6 days ago on Monday, June 9, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics